Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Arm, Prospective, Open Clinical Study of Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC With EGFR Mutation

NCT04952168 is registered in ClinicalTrials.gov with Yuan Chen as lead sponsor.

NCT NCT04952168
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04952168 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Arm, Prospective, Open Clinical Study of Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC With EGFR Mutation
Lead sponsor
Yuan Chen
Phase
Phase 2
Overall status
Unknown status
Start date
June 2, 2021
Completion date
June 2, 2023
Enrollment
26 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc, stage iii